CRSP in the 13F filings
Crispr Therapeutics AG · CUSIP H17182108
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 19
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 3 listed it in both
- Shares listed
- 15,259,353
- combined, among listed positions
- Reported value
- $800m
- combined, at the quarter end
Among the 92 comparable managers: 11 buyers (opened or added shares) and 9 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +372,780.
Managers listing CRSP in Q4 2025
19 of 19 holders
Largest increases and reductions, by shares
Increases
- ARK Investment Management LLCexisting position · 10,522,057 shares now+735,084
- Squarepoint Ops LLCnew position · 581,108 shares now+581,108
- Citadel Advisors LLCexisting position · 267,685 shares now+100,584
- Fidelity (FMR LLC)existing position · 1,953,957 shares now+68,294
- Susquehanna International Group LLPexisting position · 853,971 shares now+39,647
Reductions
- Two Sigma Investments LPexisting position · 470,621 shares now-574,068
- Two Sigma Advisers LPexisting position · 162,400 shares now-410,572
- Millennium Management LLCexisting position · 30,492 shares now-55,790
- Verition Fund Management LLCexisting position · 13,934 shares now-10,844
- AQR Capital Management LLCexisting position · 20,746 shares now-7,626
New positions and exits
New (5)
Exited (2)
- Woodline Partners LPwas $9.3m
- Voloridge Investment Management LLCwas $2.1m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2017 | 1 | $206k | n.a. | n.a. |
| Q3 2017 | 1 | $457k | n.a. | n.a. |
| Q4 2017 | 2 | $21m | n.a. | n.a. |
| Q1 2018 | 3 | $39m | n.a. | n.a. |
| Q2 2018 | 3 | $100m | n.a. | n.a. |
| Q3 2018 | 4 | $146m | n.a. | n.a. |
| Q4 2018 | 5 | $103m | n.a. | n.a. |
| Q1 2019 | 2 | $98m | n.a. | n.a. |
| Q2 2019 | 2 | $152m | n.a. | n.a. |
| Q3 2019 | 3 | $138m | n.a. | n.a. |
| Q4 2019 | 6 | $252m | n.a. | n.a. |
| Q1 2020 | 7 | $237m | n.a. | n.a. |
| Q2 2020 | 5 | $517m | n.a. | n.a. |
| Q3 2020 | 4 | $763m | n.a. | n.a. |
| Q4 2020 | 9 | $2.0bn | n.a. | n.a. |
| Q1 2021 | 4 | $1.3bn | n.a. | n.a. |
| Q2 2021 | 4 | $1.5bn | n.a. | n.a. |
| Q3 2021 | 4 | $903m | n.a. | n.a. |
| Q4 2021 | 4 | $781m | n.a. | n.a. |
| Q1 2022 | 6 | $696m | n.a. | n.a. |
| Q2 2022 | 6 | $799m | n.a. | n.a. |
| Q3 2022 | 5 | $603m | n.a. | n.a. |
| Q4 2022 | 6 | $369m | n.a. | n.a. |
| Q1 2023 | 4 | $380m | n.a. | n.a. |
| Q2 2023 | 6 | $483m | n.a. | n.a. |
| Q3 2023 | 4 | $354m | n.a. | n.a. |
| Q4 2023 | 4 | $609m | 2 | 3 |
| Q1 2024 | 4 | $595m | 2 | 2 |
| Q2 2024 | 5 | $480m | 3 | 2 |
| Q3 2024 | 4 | $403m | 1 | 5 |
| Q4 2024 | 2 | $388m | 2 | 1 |
| Q1 2025 | 3 | $414m | 3 | 0 |
| Q2 2025 | 4 | $643m | 4 | 0 |
| Q3 2025 | 4 | $748m | 0 | 4 |
| Q4 2025 | 1 | $552m | 11 | 9 |
| Q1 2026 | 4 | $840m | 16 | 5 |
| Q2 2026 | 3 | $883m | 15 | 8 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CRSP and GILD →CRSP and AMGN →CRSP and ARGX →Choose a stock to compare with CRSP →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CRSP, latest filings →Back to the 13F Explorer →